Management of bleeding emergencies: when to use recombinant activated Factor VII

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.7, Iss.1, 2006-01, pp. : 25-34

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Recombinant activated Factor VII in major surgery and trauma patients: a response

By Zakhary Randa Grob Seremetis Stephanie

Expert Opinion on Drug Safety, Vol. 4, Iss. 5, 2005-09 ,pp. : 813-814

Informa Healthcare

Access to resources Recommend Favorite

Uncontrolled Bleeding in Surgical Patients: The Role of Recombinant Activated Factor VIIa

Current Drug Targets, Vol. 10, Iss. 8, 2009-08 ,pp. : 744-770

Bentham Science Publishers

Access to resources Recommend Favorite

Eptacog-alfa [activated recombinant factor VII] is an effective, well-tolerated therapy in haemophilia patients with inhibitors

Inpharma, Vol. 1, Iss. 1572, 2007-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Determinants of Drug Costs in Hospitalised Patients with Haemophilia: Impact of Recombinant Activated Factor VII

By Galanaud J.P.

PharmacoEconomics, Vol. 21, Iss. 10, 2003-01 ,pp. : 699-707

Adis International

Access to resources Recommend Favorite

The safety and efficacy of the administration of recombinant activated factor VII in major surgery and trauma patients

By Wilson Stephen J Bellamy Mark C Giannoudis Peter V

Expert Opinion on Drug Safety, Vol. 4, Iss. 3, 2005-05 ,pp. : 557-570

Informa Healthcare

Access to resources Recommend Favorite